Author:
Dong Lianhua,Wang Shangjun,Fu Boqiang,Wang Jing
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Karapetis, C. S. et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New Engl. J. Med. 359, 1757–1765 (2008).
2. Rafael, G. A. et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J. Clin. Oncol. 26, 1626–1634 (2008).
3. Benvenuti, S. et al. Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies. Molecular Biology, Pathobiology, and Genetics 67, 2643–2648 (2007).
4. Sawyers, C. The cancer biomarker problem. Nature 452, 548–552 (2008).
5. van’t Veer, L. J. & Bernards, R. Enabling personalized cancer medicine through analysis of geneexpression patterns. Nature 452, 564–570 (2008).
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献